Human ultrarare genetic disorders of sulfur metabolism demonstrate redundancies in H2S homeostasis
Viktor Kožich,
Bernd C Schwahn,
Jitka Sokolová,
Michaela Křížková,
Tamas Ditroi,
Jakub Krijt,
Youssef Khalil,
Tomáš Křížek,
Tereza Vaculíková-Fantlová,
Blanka Stibůrková,
Philippa Mills,
Peter Clayton,
Kristýna Barvíková,
Holger Blessing,
Jolanta Sykut-Cegielska,
Carlo Dionisi-Vici,
Serena Gasperini,
Ángeles García-Cazorla,
Tobias B Haack,
Tomáš Honzík,
Pavel Ješina,
Alice Kuster,
Lucia Laugwitz,
Diego Martinelli,
Francesco Porta,
René Santer,
Guenter Schwarz,
Peter Nagy
Affiliations
Viktor Kožich
Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic; Corresponding author. Department of Pediatrics and Inherited Metabolic Disorders, Charles University, Medicine and General University Hospital in Prague, Ke Karlovu 2, 128 08, Praha 2, Czech Republic.
Bernd C Schwahn
Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester, United Kingdom
Jitka Sokolová
Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic
Michaela Křížková
Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic
Tamas Ditroi
Department of Molecular Immunology and Toxicology and the National Tumor Biology Laboratory, National Institute of Oncology, Budapest, Hungary
Jakub Krijt
Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic
Youssef Khalil
Genetics & Genomic Medicine Department, UCL GOS Institute of Child Health, London, UK
Tomáš Křížek
Department of Analytical Chemistry, Faculty of Science, Charles University, Prague, Czech Republic
Tereza Vaculíková-Fantlová
Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic
Blanka Stibůrková
Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic; Institute of Rheumatology, Prague, Czech Republic
Philippa Mills
Genetics & Genomic Medicine Department, UCL GOS Institute of Child Health, London, UK
Peter Clayton
Genetics & Genomic Medicine Department, UCL GOS Institute of Child Health, London, UK
Kristýna Barvíková
Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic
Holger Blessing
Kinder- und Jugendklinik, Universitätsklinikum Erlangen, Erlangen, Germany
Jolanta Sykut-Cegielska
Department of Inborn Errors of Metabolism and Pediatrics, The Institute of Mother and Child, Warsaw, Poland
Carlo Dionisi-Vici
Division of Metabolism, Bambino Gesù Children's Hospital IRCCS, Rome, Italy
Serena Gasperini
Metabolic Rare Diseases Unit, Department of Pediatrics, Fondazione MBBM, San Gerardo Hospital, Monza, Italy
Ángeles García-Cazorla
Inborn Errors of Metabolism Unit, Institut de Recerca Sant Joan de Déu and CIBERER-ISCIII, Barcelona, Spain
Tobias B Haack
Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany
Tomáš Honzík
Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic
Pavel Ješina
Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic
Alice Kuster
Center for Inborn Errors of Metabolism, Pediatric Intensive Care Unit, University Hospital of Nantes, Nantes, France
Lucia Laugwitz
Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany; Department of Neuropediatrics, Developmental Neurology and Social Pediatrics, University of Tübingen, Tübingen, Germany
Diego Martinelli
Division of Metabolism, Bambino Gesù Children's Hospital IRCCS, Rome, Italy
Francesco Porta
Department of Pediatrics, Metabolic diseases, AOU Città della Salute e della Scienza, University of Torino, Torino, Italy
René Santer
Department of Pediatrics, University Medical Centre Eppendorf, Hamburg, Germany
Guenter Schwarz
Institute of Biochemistry, Department of Chemistry, University of Cologne, Cologne, Germany; Corresponding author. Institute of Biochemistry, Department of Chemistry, University of Cologne, Zuelpicher Str. 4750674, Koeln, Germany.
Peter Nagy
Department of Molecular Immunology and Toxicology and the National Tumor Biology Laboratory, National Institute of Oncology, Budapest, Hungary; Department of Anatomy and Histology, ELKH-ÁTE Laboratory of Redox Biology, University of Veterinary Medicine, Budapest, Hungary; Chemistry Institute, University of Debrecen, Debrecen, Hungary; Corresponding author. Department of Molecular Immunology and Toxicology, National Institute of Oncology, 1122 Budapest, Ráth György u. 7-9., Hungary.
Regulation of H2S homeostasis in humans is poorly understood. Therefore, we assessed the importance of individual enzymes in synthesis and catabolism of H2S by studying patients with respective genetic defects. We analyzed sulfur compounds (including bioavailable sulfide) in 37 untreated or insufficiently treated patients with seven ultrarare enzyme deficiencies and compared them to 63 controls. Surprisingly, we observed that patients with severe deficiency in cystathionine β-synthase (CBS) or cystathionine γ-lyase (CSE) - the enzymes primarily responsible for H2S synthesis - exhibited increased and normal levels of bioavailable sulfide, respectively. However, an approximately 21-fold increase of urinary homolanthionine in CBS deficiency strongly suggests that lacking CBS activity is compensated for by an increase in CSE-dependent H2S synthesis from accumulating homocysteine, which suggests a control of H2S homeostasis in vivo. In deficiency of sulfide:quinone oxidoreductase - the first enzyme in mitochondrial H2S oxidation - we found normal H2S concentrations in a symptomatic patient and his asymptomatic sibling, and elevated levels in an asymptomatic sibling, challenging the requirement for this enzyme in catabolizing H2S under physiological conditions. Patients with ethylmalonic encephalopathy and sulfite oxidase/molybdenum cofactor deficiencies exhibited massive accumulation of thiosulfate and sulfite with formation of large amounts of S-sulfocysteine and S-sulfohomocysteine, increased renal losses of sulfur compounds and concomitant strong reduction in plasma total cysteine. Our results demonstrate the value of a comprehensive assessment of sulfur compounds in severe disorders of homocysteine/cysteine metabolism and provide evidence for redundancy and compensatory mechanisms in the maintenance of H2S homeostasis.